title: Association between the XRCC1 polymorphisms and glioma risk: a meta-analysis of case-control studies.
abstract: BACKGROUND
  X-ray repair cross-complementing group 1 (XRCC1) is one of the DNA repair genes encoding a scaffolding protein that participate in base excision repair (BER) pathway. However, studies on the association between polymorphisms in this gene and glioma have yielded conflicting results. This meta-analysis was performed to derive a more precise estimation between XRCC1 polymorphisms (Arg399Gln, Arg194Trp, and Arg280His) and glioma risk.
  
  
  METHODS
  Data were collected from several electronic databases, with the last search up to November 28, 2012. Meta-analysis was performed by critically reviewing 9 studies for Arg399Gln polymorphism (3146 cases and 4296 controls), 4 studies for Arg194Trp polymorphism (2557 cases and 4347 controls), and 4 studies for Arg280His polymorphism (1936 cases and 2895 controls). All of the statistical analyses were performed using the software programs STATA (version 11.0).
  
  
  RESULTS
  The combined results showed that Arg399Gln polymorphism was significantly associated with glioma risk (Gln/Gln versus Arg/Arg: OR = 1.52, 95% CI = 1.03-2.23; recessive model: OR = 1.32, 95% CI = 1.01-1.73; additive model: OR = 1.21, 95% CI = 1.00-1.47), whereas Arg194Trp/Arg280His polymorphisms were all not significantly associated with glioma risk. As for ethnicity, Arg399Gln polymorphism was associated with increased risk of glioma among Asians (Gln/Gln versus Arg/Arg: OR = 1.78, 95% CI = 1.29-2.47; Arg/Gln versus Arg/Arg: OR = 1.28, 95% CI = 1.05-1.56; recessive model: OR = 1.59, 95% CI = 1.16-2.17; dominant model: OR = 1.36, 95% CI = 1.13-1.65; additive model: OR = 1.32, 95% CI = 1.15-1.52), but not among Caucasians. Stratified analyses by histological subtype indicated that the Gln allele of Arg399Gln polymorphism showed borderline association with the risk of glioblastoma among Caucasians. However, no evidence was observed in subgroup analyses for Arg194Trp/Arg280His polymorphisms.
  
  
  CONCLUSIONS
  Our meta-analysis suggested that Arg399Gln polymorphism was associated with increased risk of glioma among Asians and borderline increased risk for glioblastoma among Caucasians, whereas Arg194Trp/Arg280His polymorphisms might have no influence on the susceptibility of glioma in different ethnicities.
authors: Department of Neurosurgery, Changzheng Hospital, Second Military Medical University, Shanghai, China.
authors: Lei
authors: L
authors: Jiang
authors: Xiao
authors: X
authors: Fang
authors: Yi
authors: Y
authors: Bao
authors: Jue-Yu
authors: JY
authors: Zhou
authors: Xiao-Yan
authors: XY
authors: Shen
authors: Mao-Hua
authors: MH
authors: Ding
authors: Yi
authors: Y
authors: Chen
authors: Guo-Han
authors: GH
authors: Hu
authors: Yi-Cheng
authors: YC
authors: Lu
mesh_terms: D016022:Case-Control Studies; D004268:DNA-Binding Proteins / Q000235:genetics*; D056726:Genetic Association Studies; D005909:Glioblastoma / Q000453:epidemiology / Q000235:genetics; D005910:Glioma / Q000453:epidemiology / Q000235:genetics*; D006801:Humans; D016017:Odds Ratio; D020641:Polymorphism, Single Nucleotide; D017594:Publication Bias; D012306:Risk; D000076105:X-ray Repair Cross Complementing Protein 1
chemical_list: D004268:DNA-Binding Proteins; D000076105:X-ray Repair Cross Complementing Protein 1; C000619371:XRCC1 protein, human
references: Br J Neurosurg. 2010 Oct;24(5):561-5
references: 20868244
references: Breast. 2009 Jun;18(3):183-91
references: 19446452
references: Breast Cancer Res Treat. 2005 Jan;89(1):15-21
references: 15666192
references: Neuroepidemiology. 2007;29(1-2):55-8
references: 17898525
references: Breast Cancer Res Treat. 2009 May;115(1):137-44
references: 18481169
references: JAMA. 1999 Nov 10;282(18):1752-9
references: 10568648
references: Cancer Res. 2004 Aug 15;64(16):5560-3
references: 15313891
references: Asian Pac J Cancer Prev. 2011;12(10):2547-50
references: 22320953
references: Asian Pac J Cancer Prev. 2002;3(3):197-206
references: 12718576
references: Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1513-30
references: 12496039
references: J Natl Cancer Inst. 1959 Apr;22(4):719-48
references: 13655060
references: Cancer Res. 1998 Feb 15;58(4):604-8
references: 9485007
references: Prostate Cancer Prostatic Dis. 2011 Sep;14(3):225-31
references: 21647176
references: Control Clin Trials. 1986 Sep;7(3):177-88
references: 3802833
references: Hepatogastroenterology. 2012 Oct;59(119):2285-9
references: 22456434
references: Asian Pac J Cancer Prev. 2011;12(9):2237-43
references: 22296363
references: Gene. 2012 Nov 10;509(2):223-7
references: 22951806
references: Science. 2001 Feb 16;291(5507):1284-9
references: 11181991
references: Cancer Epidemiol Biomarkers Prev. 2009 Dec;18(12):3384-8
references: 19959686
references: Methods Mol Biol. 2009;472:323-42
references: 19107440
references: Asian Pac J Cancer Prev. 2011;12(11):2981-4
references: 22393975
references: Int J Cancer. 2008 Jul 1;123(1):174-80
references: 18386788
references: Int J Colorectal Dis. 2010 Mar;25(3):313-21
references: 20033188
references: Urology. 2008 Oct;72(4):869-72
references: 18336890
references: DNA Cell Biol. 2007 Mar;26(3):186-91
references: 17417947
references: BMJ. 1997 Sep 13;315(7109):635-40
references: 9310564
references: Mol Biol Rep. 2012 Oct;39(10):9535-47
references: 22729882
references: PLoS One. 2012;7(9):e44441
references: 22984511
references: Cancer Epidemiol Biomarkers Prev. 2003 Nov;12(11 Pt 1):1168-74
references: 14652276
references: J Neurooncol. 2008 Jun;88(2):135-42
references: 18330515
references: Neurosciences (Riyadh). 2008 Jul;13(3):227-32
references: 21063329
references: Neuro Oncol. 2010 Jan;12(1):37-48
references: 20150366
references: Lung Cancer. 2011 Aug;73(2):138-46
references: 21195504
references: Tohoku J Exp Med. 2009 Sep;219(1):43-51
references: 19713684
references: J Thorac Oncol. 2010 Nov;5(11):1741-7
references: 20975374
references: BMJ. 1997 Sep 13;315(7109):629-34
references: 9310563
references: Int J Cancer. 2009 Sep 1;125(5):1102-9
references: 19444915
references: Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):204-14
references: 19124499
references: BMC Med Genet. 2012 Oct 26;13:97
references: 23101479
references: Hum Mol Genet. 2008 Mar 15;17(6):800-5
references: 18048407
references: Urology. 2009 Sep;74(3):648-53
references: 19428062
references: PLoS One. 2012;7(4):e34897
references: 22529951
references: Asian Pac J Cancer Prev. 2012;13(9):4783-8
references: 23167420
references: Anticancer Res. 2011 Nov;31(11):3945-52
references: 22110224
references: Nucleic Acids Res. 1995 Dec 11;23(23):4836-43
references: 8532526
references: Mol Biol Rep. 2011 Oct;38(7):4565-73
references: 21499756
references: Regul Toxicol Pharmacol. 1995 Oct;22(2):189-97
references: 8577954
references: Mol Biol Rep. 2012 Feb;39(2):1305-13
references: 21604176
references: Int J Cancer. 2005 Sep 1;116(3):428-32
references: 15800946
references: Mol Cell Biol. 1994 Jan;14(1):68-76
references: 8264637
references: Cancer Res. 2005 Feb 1;65(3):722-6
references: 15705867
references: EMBO J. 1996 Dec 2;15(23):6662-70
references: 8978692
references: Mol Biol Rep. 2013 Jan;40(1):567-72
references: 23096083
references: Leuk Lymphoma. 2013 Jan;54(1):153-9
references: 22712837
references: Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1118-26
references: 19318434
references: Int J Cancer. 2004 Sep 20;111(5):805-8
references: 15252855
references: Genet Mol Res. 2011 Jun 14;10(2):1120-9
references: 21710464
references: Annu Rev Biochem. 2004;73:39-85
references: 15189136
references: World J Gastroenterol. 2012 Aug 21;18(31):4207-14
references: 22919255
references: Protein J. 2007 Dec;26(8):541-6
references: 17899335
references: Acta Neuropathol. 2005 Jan;109(1):93-108
references: 15685439
references: BMJ. 2003 Sep 6;327(7414):557-60
references: 12958120